Moreover, in 2023 it was announced that a bispecific nanobody compound, which blocked human TNF-α and IL-6, effectively inhibited disease-relevant pathways in vitro, supporting further development of this TNF/IL-6 nanobody as a therapy for RA [70]. The gene discussed is TNF; the disease is rheumatoid arthritis.